Vaccine development for SARS COV2: -
(reverse vaccinology approach.)
(reverse vaccinology approach.)
The approach that we can take to develop vaccine is
that we can identify the structure of the surface proteins present on virus and
find the genome sequence responsible for the production of these proteins and
can engineer the DNA sequence of it by using the recombinant DNA technology.
We can copy the DNA sequence to make a huge number of
it by the PCR method which will then be utilized to make proteins in another
organism from where we would extract the proteins.
These proteins will be given along with the adjuvants
(i.e. substances that increases the efficacy of vaccine).to the patient so that
the patient’s immune system can develop an immune memory which will be utilized
whenever a virus attack.
Two companies the Sanofi and the GSK have collaborated to develop vaccine against the SARs COV2.
1) In this collaboration the Sanofi will be contributing the S-protein COVID-19 antigen which has been obtained by using the recombinant DNA technology. This technology has produced an exact genetic match to the proteins present on the viral surface and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.
2) GSK will contribute its proven pandemic adjuvant technology to the collaboration. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.
-Compiled by Curiosityseeker
Comments
Post a Comment